Sanofi (SNY) Secures Approval for Cablivi in the US and Plozasiran in China

Sanofi (NASDAQ:SNY) is one of the best blue-chip stocks to buy for 2026. On January 5, the US Food and Drug Administration announced the approval of Sanofi SA (NASDAQ:SNY)’s Cablivi. The approval covers the use of the injection to treat pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP). Sanofi (SNY) Secures Approval for Cablivi in the US and Plozasiran in China The injection was first approved in 2019 for the treatment of adults with thrombotic thromboc ...